Cytori Therapeutics, Inc. Announces Resignation of Gary Lyons as Member of the Board of Directors
February 01, 2019 at 04:15 pm EST
Share
On January 30, 2019, Gary Lyons submitted his resignation as a member of the Board of Directors of Cytori Therapeutics, Inc. effective immediately, and the Board of Directors decreased its size from five to four members. Mr. Lyons’s decision to resign did not result from any disagreement with the Company concerning any matter relating to the Company’s operations, policies or practices.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.